These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30385285)

  • 1. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface.
    Dodd S; Kollipara S; Sanchez-Felix M; Kim H; Meng Q; Beato S; Heimbach T
    J Pharm Sci; 2019 Jan; 108(1):87-101. PubMed ID: 30385285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices.
    Pepin XJH; Moir AJ; Mann JC; Sanderson NJ; Barker R; Meehan E; Plumb AP; Bailey GR; Murphy DS; Krejsa CM; Andrew MA; Ingallinera TG; Slatter JG
    Eur J Pharm Biopharm; 2019 Sep; 142():435-448. PubMed ID: 31306750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
    Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
    J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling.
    Zhu AZ; Ho MD; Gemski CK; Chuang BC; Liao M; Xia CQ
    AAPS J; 2016 Nov; 18(6):1512-1523. PubMed ID: 27600136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
    Le Merdy M; Tan ML; Sun D; Ni Z; Lee SC; Babiskin A; Zhao L
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):41-51. PubMed ID: 33064292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling.
    Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
    Eur J Pharm Sci; 2021 Mar; 158():105656. PubMed ID: 33253885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the impact of acid-reducing agents on drug absorption using biorelevant in vitro tools and PBPK modeling - case example dipyridamole.
    Segregur D; Barker R; Mann J; Moir A; Karlsson EM; Turner DB; Arora S; Dressman J
    Eur J Pharm Sci; 2021 May; 160():105750. PubMed ID: 33581261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.
    Smelick GS; Heffron TP; Chu L; Dean B; West DA; Duvall SL; Lum BL; Budha N; Holden SN; Benet LZ; Frymoyer A; Dresser MJ; Ware JA
    Mol Pharm; 2013 Nov; 10(11):4055-62. PubMed ID: 24044612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery.
    Gobeau N; Stringer R; De Buck S; Tuntland T; Faller B
    Pharm Res; 2016 Sep; 33(9):2126-39. PubMed ID: 27278908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-dependent drug-drug interactions for weak base drugs: potential implications for new drug development.
    Zhang L; Wu F; Lee SC; Zhao H; Zhang L
    Clin Pharmacol Ther; 2014 Aug; 96(2):266-77. PubMed ID: 24733008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Physiologically-Based Pharmacokinetic Modeling to Predict Gastric pH-Dependent Drug-Drug Interactions for Weak Base Drugs.
    Dong Z; Li J; Wu F; Zhao P; Lee SC; Zhang L; Seo P; Zhang L
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):456-465. PubMed ID: 32633893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.
    Sinha VK; Snoeys J; Osselaer NV; Peer AV; Mackie C; Heald D
    Biopharm Drug Dispos; 2012 Mar; 33(2):111-21. PubMed ID: 22383166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Oral Absorption Modelling to Study Gut-Level Drug Interactions.
    Chung J; Kesisoglou F
    J Pharm Sci; 2018 Jan; 107(1):18-23. PubMed ID: 28847476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic Physiologically Based Pharmacokinetic Modeling of the Dissolution and Food Effect of a Biopharmaceutics Classification System IV Compound-The Venetoclax Story.
    Emami Riedmaier A; Lindley DJ; Hall JA; Castleberry S; Slade RT; Stuart P; Carr RA; Borchardt TB; Bow DAJ; Nijsen M
    J Pharm Sci; 2018 Jan; 107(1):495-502. PubMed ID: 28993217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An
    Piscitelli J; Hens B; Tomaszewska I; Wollenberg L; Litwiler K; McAllister M; Reddy M
    Mol Pharm; 2023 May; 20(5):2589-2599. PubMed ID: 37037186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility.
    Chung J; Alvarez-Nunez F; Chow V; Daurio D; Davis J; Dodds M; Emery M; Litwiler K; Paccaly A; Peng J; Rock B; Wienkers L; Yang C; Yu Z; Wahlstrom J
    J Pharm Sci; 2015 Apr; 104(4):1522-32. PubMed ID: 25641187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs.
    Melillo N; Aarons L; Magni P; Darwich AS
    J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.